CN112955474A - 长效纤连蛋白iii型结构域融合蛋白 - Google Patents

长效纤连蛋白iii型结构域融合蛋白 Download PDF

Info

Publication number
CN112955474A
CN112955474A CN201980047762.8A CN201980047762A CN112955474A CN 112955474 A CN112955474 A CN 112955474A CN 201980047762 A CN201980047762 A CN 201980047762A CN 112955474 A CN112955474 A CN 112955474A
Authority
CN
China
Prior art keywords
type iii
fibronectin type
iii domain
fusion protein
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980047762.8A
Other languages
English (en)
Inventor
王峰
郑花鸯
张雨菡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nantong Yichen Biomedical Technology Co ltd
Original Assignee
Shanghai Yichen Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Yichen Pharmaceutical Technology Co ltd filed Critical Shanghai Yichen Pharmaceutical Technology Co ltd
Publication of CN112955474A publication Critical patent/CN112955474A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明属于生物技术制药领域，具体涉及一种含有纤连蛋白III型结构域的融合蛋白及其制备与应用。所述融合蛋白的结构包括：纤连蛋白III型结构域和插入序列。本发明的纤连蛋白III型结构域融合蛋白，能够保持插入蛋白或活性肽的空间构象，并能够有效保护目标蛋白的N端和/或C端，使得目标蛋白不易被酶解，因此其体内半衰期更长，在临床上有望实现三周甚至一月一次的给药频率；所述融合蛋白的生产和制备工艺和抗体相似，产物表达量大；并且所述融合蛋白不会产生在体内无法降解的副作用。

Description

PCT国内申请，说明书已公开。

Claims (42)

  1. PCT国内申请，权利要求书已公开。
CN201980047762.8A 2018-07-17 2019-07-17 长效纤连蛋白iii型结构域融合蛋白 Pending CN112955474A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810784128.XA CN110724198B (zh) 2018-07-17 2018-07-17 长效纤连蛋白iii型结构域融合蛋白
CN201810784128X 2018-07-17
PCT/CN2019/096357 WO2020015677A1 (zh) 2018-07-17 2019-07-17 长效纤连蛋白iii型结构域融合蛋白

Publications (1)

Publication Number Publication Date
CN112955474A true CN112955474A (zh) 2021-06-11

Family

ID=69163984

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810784128.XA Active CN110724198B (zh) 2018-07-17 2018-07-17 长效纤连蛋白iii型结构域融合蛋白
CN201980047762.8A Pending CN112955474A (zh) 2018-07-17 2019-07-17 长效纤连蛋白iii型结构域融合蛋白

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201810784128.XA Active CN110724198B (zh) 2018-07-17 2018-07-17 长效纤连蛋白iii型结构域融合蛋白

Country Status (3)

Country Link
US (1) US20210300995A1 (zh)
CN (2) CN110724198B (zh)
WO (1) WO2020015677A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116836264A (zh) * 2023-06-01 2023-10-03 广东完美生命健康科技研究院有限公司 一种重组人源化纤连蛋白rhFEB及应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110724198B (zh) * 2018-07-17 2023-05-26 上海一宸医药科技有限公司 长效纤连蛋白iii型结构域融合蛋白
CN113912735A (zh) * 2020-07-08 2022-01-11 南京师范大学 多肽二聚体及其用途
EP4186928A4 (en) * 2020-07-08 2024-10-09 Nanjing Normal University FUSION POLYPEPTIDE AND POLYPEPTIDE DIMER, AND USE THEREOF
CN112876569B (zh) * 2021-02-08 2022-05-10 芜湖天明生物技术有限公司 一种rhTSG6-FNⅢ1-C融合蛋白及其在皮肤护理组合物中的用途和其制备方法
CN115197966A (zh) * 2022-08-15 2022-10-18 深圳源兴基因技术有限公司 一种利用生物反应器大规模生产重组痘苗病毒载体的方法
CN117264047B (zh) * 2023-09-21 2024-05-17 南京巴凯星生物科技有限公司 一种重组iii型人源化胶原蛋白氨基酸序列及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017210425A1 (en) * 2016-06-03 2017-12-07 Janssen Biotech, Inc. Serum albumin-binding fibronectin type iii domains
CN108179152A (zh) * 2017-12-29 2018-06-19 大连大学 一种基于人纤维连接蛋白ⅲ型结构域展示双抗原表位制备抗原替代物的方法
CN110724198A (zh) * 2018-07-17 2020-01-24 上海一宸医药科技有限公司 长效纤连蛋白iii型结构域融合蛋白

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2010121967A (ru) * 2007-10-31 2011-12-10 Медиммун, Ллк (Us) Белковые каркасные структуры
US20130079280A1 (en) * 2010-04-13 2013-03-28 Medlmmune, Llc Fibronectin type iii domain-based multimeric scaffolds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017210425A1 (en) * 2016-06-03 2017-12-07 Janssen Biotech, Inc. Serum albumin-binding fibronectin type iii domains
CN108179152A (zh) * 2017-12-29 2018-06-19 大连大学 一种基于人纤维连接蛋白ⅲ型结构域展示双抗原表位制备抗原替代物的方法
CN110724198A (zh) * 2018-07-17 2020-01-24 上海一宸医药科技有限公司 长效纤连蛋白iii型结构域融合蛋白

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116836264A (zh) * 2023-06-01 2023-10-03 广东完美生命健康科技研究院有限公司 一种重组人源化纤连蛋白rhFEB及应用
CN116836264B (zh) * 2023-06-01 2024-02-20 广东完美生命健康科技研究院有限公司 一种重组人源化纤连蛋白rhFEB及应用

Also Published As

Publication number Publication date
CN110724198A (zh) 2020-01-24
WO2020015677A1 (zh) 2020-01-23
CN110724198B (zh) 2023-05-26
US20210300995A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
CN112955474A (zh) 长效纤连蛋白iii型结构域融合蛋白
CN107759697B (zh) 制备融合蛋白的方法
Strohl Fusion proteins for half-life extension of biologics as a strategy to make biobetters
ES2780948T3 (es) Proteínas de fusión de inmunoglobulinas en hélice enrollada y composiciones de las mismas
Sleep et al. Albumin as a versatile platform for drug half-life extension
JP6448368B2 (ja) 免疫グロブリンＦｃ変異体
EP2502939B1 (en) Nonnatural collagen-like protein and use thereof
US20160376346A1 (en) Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS
KR20170065026A (ko) 대사 장애 치료용으로 이용되는 조성물 및 방법
JP2017518049A (ja) アミノ末端免疫グロブリン融合タンパク質とその組成物を構築する方法
EP2585098B1 (en) Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules for use in treating obesity and obesity-related disorders
CN108348581B (zh) 胰岛素免疫球蛋白融合蛋白
MX2012011781A (es) Proteinas de dominio de armazon basadas en fibronectina que se unen a la proteina convertasa subtilisina kexina tipo q (pcsk9).
TWI693236B (zh) 保留免疫球蛋白Ｆｃ片段對ＦｃＲｎ之結合親和力之免疫球蛋白Ｆｃ接合物
CN104271604A (zh) 制备生理活性多肽复合物的改进方法
TWI647240B (zh) 生理活性多肽複合物高產率製備之改良製程
CN103641896A (zh) 明胶样单元的用途
US20180127478A1 (en) SINGLE CHAIN Fc-DIMER-HUMAN GROWTH HORMONE FUSION PROTEIN FOR IMPROVED DRUG DELIVERY
CN106008717B (zh) 一种长效重组glp-1融合蛋白及其制备方法和用途
CN106957365B (zh) 一种单克隆抗体FnAb8及其应用
CN106957364B (zh) 一种单克隆抗体FnAb12及其应用
CN103044554A (zh) 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
JP7136690B2 (ja) 免疫グロブリン融合タンパク質およびその使用
Ali-Hassan The Development of Biological
Zhou Developing Recombinant Single Chain Fc-Dimer Fusion Proteins for Improved Protein Drug Delivery

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20210621

Address after: 226000 320, building 6, Zilang science and Technology City, 60 Chongzhou Avenue, Nantong City, Jiangsu Province

Applicant after: Nantong Yichen Biomedical Technology Co.,Ltd.

Address before: Room 1107-a, building 67, 421 Hongcao Road, Xuhui District, Shanghai 200233

Applicant before: Shanghai Yichen Pharmaceutical Technology Co.,Ltd.

TA01 Transfer of patent application right